STOCK TITAN

[Form 3] Avalo Therapeutics, Inc. Initial Statement of Beneficial Ownership

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
3

Boyd Taylor, identified as Chief Business Officer and a director, filed an initial Form 3 for Avalo Therapeutics, Inc. (AVTX) reporting the event date 10/01/2025. The filing states no securities are beneficially owned by the reporting person. The form was signed under power of attorney by Donald R. Reynolds on 10/06/2025. The submission confirms an initial disclosure with no ownership to report.

Boyd Taylor, identificato come Direttore Generale degli Affari e un membro del consiglio di amministrazione, ha presentato un primo Modulo 3 per Avalo Therapeutics, Inc. (AVTX) riportando la data dell'evento 10/01/2025. La dichiarazione indica che nessuna partecipazione titolare è detenuta dal soggetto che riporta. Il modulo è stato firmato per procura da Donald R. Reynolds in data 10/06/2025. La presentazione conferma una divulgazione iniziale senza proprietà da segnalare.

Boyd Taylor, identificado como Director Ejecutivo de Negocios y un director, presentó un Formulario 3 inicial para Avalo Therapeutics, Inc. (AVTX) reportando la fecha del evento 10/01/2025. La declaración indica que ninguna participación de valores es propiedad del informante. El formulario fue firmado por poder por Donald R. Reynolds el 06/10/2025. La presentación confirma una divulgación inicial sin propiedad que reportar.

Boyd Taylor최고 사업 책임자이자 이사로 식별되며, Avalo Therapeutics, Inc. (AVTX)를 위한 최초의 폼 3를 제출하여 이벤트 날짜를 10/01/2025로 보고했습니다. 제출서에는 보고자에 의해 자신의 유가증권이 소유되지 않음이 명시되어 있습니다. 이 양식은 Donald R. Reynolds가 위임장으로 서명했으며 10/06/2025에 제출되었습니다. 제출은 소유권이 보고될 것이 없는 초기 공시를 확인합니다.

Boyd Taylor, identifié comme Directeur Régional des Affaires et un administrateur, a déposé une première Formulaire 3 pour Avalo Therapeutics, Inc. (AVTX) en indiquant la date de l'événement 10/01/2025. Le dépôt indique qu'aucun titre n'est détenu par la personne déclarant. Le formulaire a été signé par procuration par Donald R. Reynolds le 10/06/2025. La soumission confirme une divulgation initiale sans propriété à déclarer.

Boyd Taylor, identifiziert als Chief Business Officer und ein Direktor, hat ein initiales Formular 3 für Avalo Therapeutics, Inc. (AVTX) eingereicht und dabei das Ereignisdatum 10/01/2025 angegeben. Die Einreichung lautet, dass keine Wertpapiere vorteilhaft von der meldenden Person gehalten werden. Das Formular wurde am 10/06/2025 von Donald R. Reynolds mittels Vollmacht unterschrieben. Die Einreichung bestätigt eine初liche Offenlegung ohne Eigentum zu melden.

Boyd Taylor، المعروف بأنه المدير التنفيذي للأعمال وعضو مجلس الإدارة، قد قدّم نموذجاً أولياً Form 3 لشركة Avalo Therapeutics, Inc. (AVTX) من التاريخ 10/01/2025، مع الإشارة إلى أن لم يملك مقدم البلاغ أي أوراق مالية كمالك مستفيد. تم توقيع النموذج بتوكيل من Donald R. Reynolds في تاریخ 10/06/2025. تؤكد الإرسالية أن الإبلاغ الأولي بدون ملكية للإبلاغ عنها.

Boyd Taylor,被认定为首席商务官和一位董事,代表Avalo Therapeutics, Inc.(AVTX)提交了一份初始的表格3,事件日期为10/01/2025。该申报表示报告人并无受益所有的证券。该表格由Donald R. Reynolds2025/10/06通过授权签署。此次提交确认为初始披露,无需报告所有权。

Positive
  • None.
Negative
  • None.

Boyd Taylor, identificato come Direttore Generale degli Affari e un membro del consiglio di amministrazione, ha presentato un primo Modulo 3 per Avalo Therapeutics, Inc. (AVTX) riportando la data dell'evento 10/01/2025. La dichiarazione indica che nessuna partecipazione titolare è detenuta dal soggetto che riporta. Il modulo è stato firmato per procura da Donald R. Reynolds in data 10/06/2025. La presentazione conferma una divulgazione iniziale senza proprietà da segnalare.

Boyd Taylor, identificado como Director Ejecutivo de Negocios y un director, presentó un Formulario 3 inicial para Avalo Therapeutics, Inc. (AVTX) reportando la fecha del evento 10/01/2025. La declaración indica que ninguna participación de valores es propiedad del informante. El formulario fue firmado por poder por Donald R. Reynolds el 06/10/2025. La presentación confirma una divulgación inicial sin propiedad que reportar.

Boyd Taylor최고 사업 책임자이자 이사로 식별되며, Avalo Therapeutics, Inc. (AVTX)를 위한 최초의 폼 3를 제출하여 이벤트 날짜를 10/01/2025로 보고했습니다. 제출서에는 보고자에 의해 자신의 유가증권이 소유되지 않음이 명시되어 있습니다. 이 양식은 Donald R. Reynolds가 위임장으로 서명했으며 10/06/2025에 제출되었습니다. 제출은 소유권이 보고될 것이 없는 초기 공시를 확인합니다.

Boyd Taylor, identifié comme Directeur Régional des Affaires et un administrateur, a déposé une première Formulaire 3 pour Avalo Therapeutics, Inc. (AVTX) en indiquant la date de l'événement 10/01/2025. Le dépôt indique qu'aucun titre n'est détenu par la personne déclarant. Le formulaire a été signé par procuration par Donald R. Reynolds le 10/06/2025. La soumission confirme une divulgation initiale sans propriété à déclarer.

Boyd Taylor, identifiziert als Chief Business Officer und ein Direktor, hat ein initiales Formular 3 für Avalo Therapeutics, Inc. (AVTX) eingereicht und dabei das Ereignisdatum 10/01/2025 angegeben. Die Einreichung lautet, dass keine Wertpapiere vorteilhaft von der meldenden Person gehalten werden. Das Formular wurde am 10/06/2025 von Donald R. Reynolds mittels Vollmacht unterschrieben. Die Einreichung bestätigt eine初liche Offenlegung ohne Eigentum zu melden.

SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Boyd Taylor

(Last) (First) (Middle)
C/O AVALO THERAPEUTICS, INC.
1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)
WAYNE PA 19087

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
10/01/2025
3. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Business Officer
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
No securities are beneficially owned.
/s/ Donald R. Reynolds, by Power of Attorney 10/06/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Boyd Taylor disclose on the Form 3 for AVTX?

The filing states that Boyd Taylor (Chief Business Officer and director) does not beneficially own any securities of Avalo Therapeutics as of 10/01/2025.

What is the reporting date on the Form 3 for Avalo Therapeutics (AVTX)?

The event date listed on the Form 3 is 10/01/2025.

Who signed the Form 3 and when was it signed?

The form was signed under power of attorney by Donald R. Reynolds on 10/06/2025.

Does the Form 3 show any derivative or non-derivative securities owned?

No. The filing explicitly states "No securities are beneficially owned."

What roles does the reporting person hold at Avalo Therapeutics?

The filing indicates the reporting person is an Officer (Chief Business Officer) and a Director of Avalo Therapeutics.
Avalo Therapeutics Inc

NASDAQ:AVTX

AVTX Rankings

AVTX Latest News

AVTX Latest SEC Filings

AVTX Stock Data

184.13M
11.35M
5.26%
64.11%
0.42%
Biotechnology
Pharmaceutical Preparations
Link
United States
WAYNE